<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach</title>
  </titleInfo>
  <name type="personal">
    <namePart>Rezaei, Nima.</namePart>
    <role>
      <roleTerm type="text">editor.</roleTerm>
    </role>
    <role>
      <roleTerm authority="marcrelator" type="code">edt</roleTerm>
    </role>
    <role>
      <roleTerm authority="marcrelator" type="code">http://id.loc.gov/vocabulary/relators/edt</roleTerm>
    </role>
  </name>
  <name type="corporate">
    <namePart>SpringerLink (Online service)</namePart>
  </name>
  <typeOfResource>text</typeOfResource>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">sz</placeTerm>
    </place>
    <dateIssued encoding="marc">2024</dateIssued>
    <edition>1st ed. 2024.</edition>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">electronic</form>
    <form authority="gmd">electronic resource</form>
    <reformattingQuality>access</reformattingQuality>
    <extent>XI, 435 p. 24 illus. in color. online resource.</extent>
  </physicalDescription>
  <abstract>Genetics have a role in the presence of breast cancer, while the potential role of the immune system leads to consideration of immunotherapy in the treatment of the disease, particularly in metastatic triple-negative breast cancer. The sixth volume of the “Interdisciplinary Cancer Research” series, entitled “Breast Cancer Genetics, Immunology, and Immunotherapy: An Interdisciplinary Approach” publishes comprehensive volumes on immune and genetic mechanisms of breast cancer diagnosis and prognosis. The role of molecular genetics, interleukins, chemokine receptor, and tumor-infiltrated lymphocytes-TILS in breast cancer are explained. Targeting myeloid determinants, SiRNA loaded in drug delivery nanosystems, nucleic acid and drug dual agent nanoplatforms, and oncolytic virotherapy are also discussed in the treatment of breast cancer, particularly in multidrug resistant and metastatic breast cancer. This interdisciplinary series is of special value to researchers working on immunology, genetics, and practitioners working on oncology. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value to researchers, oncologists, geneticists, and immunologists who wish to extend their knowledge on breast cancer.</abstract>
  <tableOfContents>Role of miRNAs in Triple-Negative Breast Cancer: Diagnosis, Prognosis, and Treatment -- Approaches to Breast Cancer Immunology and Immunotherapy -- Molecular Genetics of Breast Cancer: From Mechanistic Insights to the Therapeutic Approaches -- Interleukins in the Development and Progression of Breast Cancer -- Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer -- The Prognostic Impact of Tumor-Infiltrated Lymphocytes (TILs) in Breast Cancer -- From Genes to Recovery: Precision Medicine and Its Influence on Multidrug Resistant Breast Cancer -- Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment -- Targeting Myeloid Determinants of Breast Cancer -- siRNA Loaded in Drug Delivery Nanosystems as a Strategy for Breast Cancer Treatment -- Nucleic Acid and Drug Dual Agent Nanoplatforms for Breast Cancer -- Oncolytic Virotherapy Against Breast Cancer -- Overcoming Breast Cancer Resistance to Targeted, Chemo-, and Immuno Therapy: Mechanisms and Strategies to Overcome Resistance and Facilitate Drug Development.</tableOfContents>
  <note type="statement of responsibility">edited by Nima Rezaei.</note>
  <subject authority="lcsh">
    <topic>Cancer</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Cancer</topic>
    <topic>Treatment</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Cancer</topic>
    <topic>Genetic aspects</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Oncology</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Tumors</topic>
    <topic>Immunological aspects</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Immunotherapy</topic>
  </subject>
  <subject>
    <topic>Cancer Biology</topic>
  </subject>
  <subject>
    <topic>Cancer Therapy</topic>
  </subject>
  <subject>
    <topic>Cancer Genetics and Genomics</topic>
  </subject>
  <subject>
    <topic>Oncology</topic>
  </subject>
  <subject>
    <topic>Tumour Immunology</topic>
  </subject>
  <subject>
    <topic>Immunotherapy</topic>
  </subject>
  <classification authority="lcc">RC261-271</classification>
  <relatedItem type="host">
    <titleInfo>
      <title>Springer Nature eBook</title>
    </titleInfo>
  </relatedItem>
  <relatedItem type="otherFormat" displayLabel="Printed edition:"/>
  <relatedItem type="otherFormat" displayLabel="Printed edition:"/>
  <relatedItem type="otherFormat" displayLabel="Printed edition:"/>
  <relatedItem type="series">
    <titleInfo>
      <title>Interdisciplinary Cancer Research, 6</title>
    </titleInfo>
  </relatedItem>
  <identifier type="isbn">9783031658082</identifier>
  <identifier type="uri">https://doi.org/10.1007/978-3-031-65808-2</identifier>
  <location>
    <url>https://doi.org/10.1007/978-3-031-65808-2</url>
  </location>
  <recordInfo>
    <recordCreationDate encoding="marc">240719</recordCreationDate>
    <recordChangeDate encoding="iso8601">20251030112931.0</recordChangeDate>
    <recordIdentifier source="DE-He213">978-3-031-65808-2</recordIdentifier>
  </recordInfo>
</mods>
